Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease

NCT04537377 is registered in ClinicalTrials.gov with Vivet Therapeutics SAS as lead sponsor.

NCT NCT04537377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04537377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease
Lead sponsor
Vivet Therapeutics SAS
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 3, 2021
Completion date
June 18, 2029
Enrollment
4 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

wilson's disease